SHANGHAI – Beigene Ltd. nabbed the Asia-Pacific rights to sitravatinib from Mirati Therapeutics Inc. in a $10 million cash deal, valued at $123 million when additional milestones roll in. The Beijing-based firm also just announced a $750 million public offering to support its growing immuno-oncology pipeline.